Pirfenidone CAS: 53179-13-8

CAS NO: 53179-13-8
Pirfenidone
Chemical Name: Pirfenidone
Molecular Formula: C12H11NO
Formula Weight: 185.22
CAS No.: 53179-13-8
Description Review
Description

Pirfenidone CAS: 53179-13-8 is a medication that has been approved for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and inflammation in the lungs. It is also being studied for its potential to treat other conditions such as liver fibrosis and kidney disease.

Chemical Name:

Pirfenidone is also known as 5-methyl-1-phenyl-2-(1H)-pyridone.

Molecular Formula:

The molecular formula of Pirfenidone is C12H11NO.

Formula Weight:

The formula weight of Pirfenidone is 185.22 g/mol.

CAS No:

The CAS number of Pirfenidone is 53179-13-8.

Top Ten Keywords from Google and Synonyms:

  1. Idiopathic Pulmonary Fibrosis Treatment
  2. Anti-Fibrotic Medication
  3. Lung Disease Treatment
  4. Liver Fibrosis Treatment
  5. Kidney Disease Treatment
  6. Inflammation Reducer
  7. Immunosuppressant Agent
  8. Anti-Inflammatory Drug
  9. Connective Tissue Disorder Treatment
  10. Fibrosis Modulator

Health Benefits of Pirfenidone:

Pirfenidone is primarily used to treat idiopathic pulmonary fibrosis (IPF). However, it has also shown potential to treat other conditions such as liver fibrosis and kidney disease. Some of the potential benefits of Pirfenidone include:

  1. Reduced Lung Scarring: Pirfenidone can reduce the scarring and inflammation in the lungs caused by IPF.

  2. Improved Lung Function: Pirfenidone can improve lung function and quality of life in individuals with IPF.

  3. Reduced Liver and Kidney Fibrosis: Pirfenidone may reduce the fibrosis or scarring in the liver and kidneys caused by certain diseases.

Potential Effects:

Pirfenidone can produce a range of effects depending on the condition being treated and individual response. Some of the potential effects of Pirfenidone include:

  1. Reduced Lung Scarring: Pirfenidone can reduce the scarring and inflammation in the lungs caused by IPF.

  2. Improved Lung Function: Pirfenidone can improve lung function and quality of life in individuals with IPF.

  3. Reduced Liver and Kidney Fibrosis: Pirfenidone may reduce the fibrosis or scarring in the liver and kidneys caused by certain diseases.

Product Mechanism:

Pirfenidone works by reducing inflammation and preventing fibrosis, or the excessive production of connective tissue that can lead to scarring and organ dysfunction. It does this by blocking several pathways involved in fibrosis and inflammation, including TGF-beta, TNF-alpha, and IL-1 beta signaling.

Safety:

Pirfenidone is generally safe when used appropriately and under medical supervision. However, it can cause adverse effects in some individuals. Some of the potential side effects of Pirfenidone include:

  1. Nausea: Pirfenidone may cause nausea or gastrointestinal disturbances in some individuals.

  2. Skin Rash: Pirfenidone may cause a skin rash in some individuals.

  3. Photosensitivity: Pirfenidone may increase sensitivity to sunlight.

Dosing Information:

The appropriate dose of Pirfenidone depends on the individual's age, weight, and health status. It is important to follow dosing instructions carefully and only use Pirfenidone under medical supervision.

Conclusion:

Pirfenidone is a medication that has been approved for the treatment of idiopathic pulmonary fibrosis (IPF) and is being studied for its potential to treat other conditions such as liver fibrosis and kidney disease. It works by reducing inflammation and preventing fibrosis, or the excessive production of connective tissue that can lead to scarring and organ dysfunction. While Pirfenidone may provide some health benefits, it should only be used under medical supervision and with caution due to its potential side effects

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code